




PHARMACEUTICAL 2019

Apellis Pharmaceuticals Inc.
Rank 152 of 363





PHARMACEUTICAL 2019

Apellis Pharmaceuticals Inc.
Rank 152 of 363



The relative strengths and weaknesses of Apellis Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Apellis Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 116% points. The greatest weakness of Apellis Pharmaceuticals Inc. is the variable Other Net Income, reducing the Economic Capital Ratio by 101% points.

The company's Economic Capital Ratio, given in the ranking table, is 121%, being 85% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	202,439
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	17,025
Liabilities, Non-Current	0
Other Assets	1,094
Other Compr. Net Income	-123
Other Expenses	2,427
Other Liabilities	25,536
Other Net Income	-125,075
Other Revenues	0
Property and Equipment	0
Research and Development	0
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	203,534
Liabilities	42,561
Expenses	2,427
Revenues	0
Stockholders Equity	160,973
Net Income	-127,502
Comprehensive Net Income	-127,564
Economic Capital Ratio	121%